在血管激素受体-尼普利利辛抑制剂治疗期间错误地提高尿液C:一个病例报告
Akihiro Morishige1, Mitsuaki Nishioka1, Yoko Nakabayashi2
1Division of Laboratory, Yamaguchi University Hospital, Ube, Japan.
Annals of clinical biochemistry
|March 16, 2026
概括
ангиотензин受体-neprilysin抑制剂 (ARNI) 治疗可能会错误地提高尿中C-水平,影响糖尿病管理. 停止ARNI治疗使这些水平正常化,突出显示了这种药物相互作用在临床实践中的重要性.
科学领域:
- 内分泌学 在内分泌学.
- 临床化学 临床化学
背景情况:
- 尿液C测试评估胰腺β细胞的胰岛素分泌.
- ангиотензин受体-neprilysin抑制剂 (ARNI) 用于心力衰竭和高血压.
- 需要调查ARNI和C-代谢之间的潜在药物相互作用.
研究的目的:
- 在ARNI治疗期间报告尿液C升高的病例.
- 调查ARNI对C-测量的影响.
- 为了强调对胰岛素分泌能力的准确评估.
主要方法:
- 一个患有2型糖尿病和高血压的患者在ARNI上的病例报告.
- 同时血清和尿液C-水平的比较.
- 关于ARNI和C-代谢的文献综述.
- 在停止ARNI后监测尿中C水平.
主要成果:
- 一名接受ARNI治疗的患者在尿液中表现出明显高的C-水平与正常血清水平.
- 在停止ARNI治疗后,尿中的C水平大幅下降.
- 研究结果表明,ARNI会干扰C-的代谢或分泌.
结论:
- 使用ARNI可能导致尿中C-水平错误升高.
- 血清和尿液C之间的差异需要对ARNI使用进行调查.
- 临床实验室应了解这种相互作用,以准确评估胰岛素分泌量.
相关概念视频
Nephrotic Syndrome II : Assessment and Medical Management
295
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
295
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K
Serum Studies: Renal Function Tests
581
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
581
Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
536
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
536
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K


